<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134668">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348542</url>
  </required_header>
  <id_info>
    <org_study_id>35933</org_study_id>
    <nct_id>NCT01348542</nct_id>
  </id_info>
  <brief_title>Study of Trazodone &amp; Cognitive Behavioral Therapy to Treat Insomnia</brief_title>
  <official_title>Efficacy of Trazodone vs. Cognitive Behavioral Therapy in Patients With Chronic Insomnia Associated With Objective Short Sleep Duration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of a 3 month medication trial of
      Trazodone versus 3 months of Cognitive Behavioral Therapy (CBT) in patients with chronic
      insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with chronic insomnia associated with objective short sleep duration will be
      recruited to participate in a 3 month clinical trial on the efficacy of trazodone versus
      CBT. The primary outcome measure will be objective sleep duration as measured by both
      actigraphy and polysomnography. The secondary outcome measure will be subjective severity of
      sleep disturbance and subjective sleep duration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in objective sleep duration at 9 months</measure>
    <time_frame>Baseline, 3 months &amp; 9 months</time_frame>
    <description>Polysomnography &amp; Actigraphy will be used to measure sleep duration at baseline, post treatment (3 months) and follow-up (9 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Subjective Severity of Sleep Disturbance &amp; Subjective Sleep Duration at 9 months</measure>
    <time_frame>Baseline, 3 months &amp; 9 months</time_frame>
    <description>Sleep Diary and subjective questionnaires will be used to measure severity of sleep disturbance and subjective sleep duration at baseline, post treatment (3 months) and follow-up (9 months).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Trazodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>50 mg once a day, for 3 months</description>
    <arm_group_label>Trazodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>The CBT Protocol is implemented over a period of 12 weeks, with consultations held on a weekly basis.</description>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic insomnia with duration of more than 1 year

          -  Objective short sleep duration (&lt; 6 hours)

          -  BMI &lt; 39

          -  Ages 30-60

          -  Men &amp; Women

        Exclusion Criteria:

          -  Major Mental Illness

          -  Substance Abuse/Dependence

          -  Sleep Apnea

          -  Periodic Limb Movement Disorder

          -  Shift Work or circadian disorders

          -  Diabetes

          -  Chronic Renal Failure, Hepatic Insufficiency, Chronic Heart Failure

          -  Current Use of hypnotics or sleep inducing sedative antidepressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros N Vgontzas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carrie A Criley, BA, RPSGT</last_name>
    <phone>717 531-4123</phone>
    <email>ccriley@psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julio Fernandez-Mendoza, PhD</last_name>
    <phone>717 531-0003</phone>
    <phone_ext>285570</phone_ext>
    <email>jfernandezmendoza@hmc.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie A Criley, BA, RPSGT</last_name>
      <phone>717-531-4123</phone>
      <email>ccriley@psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julio Fernandez-Mendoza, PhD</last_name>
      <phone>717 531-0003</phone>
      <phone_ext>285570</phone_ext>
      <email>jfernandezmendoza@hmc.psu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandros N Vgontzas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Basta M, Fern√°ndez-Mendoza J, Bixler EO. Insomnia with short sleep duration and mortality: the Penn State cohort. Sleep. 2010 Sep;33(9):1159-64.</citation>
    <PMID>20857861</PMID>
  </reference>
  <reference>
    <citation>Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. Diabetes Care. 2009 Nov;32(11):1980-5. doi: 10.2337/dc09-0284. Epub 2009 Jul 29.</citation>
    <PMID>19641160</PMID>
  </reference>
  <reference>
    <citation>Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009 Apr;32(4):491-7.</citation>
    <PMID>19413143</PMID>
  </reference>
  <reference>
    <citation>Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, Kales A, Chrousos GP. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab. 2001 Aug;86(8):3787-94.</citation>
    <PMID>11502812</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Mendoza J, Calhoun S, Bixler EO, Pejovic S, Karataraki M, Liao D, Vela-Bueno A, Ramos-Platon MJ, Sauder KA, Vgontzas AN. Insomnia with objective short sleep duration is associated with deficits in neuropsychological performance: a general population study. Sleep. 2010 Apr;33(4):459-65.</citation>
    <PMID>20394314</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Mendoza J, Calhoun SL, Bixler EO, Karataraki M, Liao D, Vela-Bueno A, Jose Ramos-Platon M, Sauder KA, Basta M, Vgontzas AN. Sleep misperception and chronic insomnia in the general population: role of objective sleep duration and psychological profiles. Psychosom Med. 2011 Jan;73(1):88-97. doi: 10.1097/PSY.0b013e3181fe365a. Epub 2010 Oct 26.</citation>
    <PMID>20978224</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>April 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Alexandros Vgontzas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic Insomnia</keyword>
  <keyword>Short Sleep Duration</keyword>
  <keyword>Trazodone</keyword>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
